Special Segment: Soft Tissue Matrices—Apligraf Bilayered Skin Substitute to Augment Healing of Chronic Wounds in Diabetic Patients

Foot & Ankle Specialist

Volumn 2, Issue 6, 2009, Pages 299-302

  DeCarbo, William T ^a  

^a Orthopedic Foot Ankle Center Westerville   (United States)

Author keywords

Apligraf; autograft; bioengineered tissue; diabetic foot ulcers; tissue engineering

Indexed keywords

ARTICLE; ARTIFICIAL SKIN; DIABETIC FOOT; HUMAN; TISSUE ENGINEERING; WOUND HEALING;

DIABETIC FOOT; HUMANS; SKIN, ARTIFICIAL; TISSUE ENGINEERING; WOUND HEALING;

EID: 77954927256     PISSN: 19386400     EISSN: None     Source Type: Journal    
DOI: 10.1177/1938640009354041     Document Type: Article

References (18)

1. Kirsner RS, Falanga V., Eaglstein WH The development of bioengineered skin. Trends Biotechnol. 1998; 16: 249-249.
2. Dinh TL, Veves A. The efficacy of Apligraf in the treatment of diabetic foot ulcers. Plast Reconstr Surg. 2006; 117(7 suppl):152S-157S.
3. Mayfield JA, Reiber GE, Sanders LJ, Janisse D., Pogach LM Preventive foot care in people with diabetes. Diabetes Care. 1998; 21: 2161-2177.
4. Palumbo PJ, Melton LJ III. Peripheral vascular disease and diabetes. In: Diabetes in America: Diabetes Data Complied 1984. (NIH publication no. 85-1468). Washington, DC: Government Printing Office; 1985: XV-1-XV-21.
5. Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. Diabetes Care. 1999;22:1354-1360.
6. Singh N., Armstong DG, Lipsky BA Preventing foot ulcers in patients with diabetes. JAMA. 2005; 293(2):217-228.
7. Boulton AJM, Vileikyte L., Ragnarson-Tennvall G., Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005; 366: 1719-1724.
8. Reiber GE, Vileikyte L., Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999; 22: 157-162.
9. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. N Engl J Med. 2004; 351: 48-55.
10. Zacur H., Kirsner RS Debridement: rationale and therapeutic options. Wounds. 2002; 14(suppl E):2E-7E.
11. Mueller MJ, Diamond JE, Sinacore DR, et al. Total contact casting in treatment of diabetic plantar ulcers: controlled clinical trial. Diabetes Care. 1989; 12: 384-388.
12. Armstrong DG, Nguyen HC, Lavery LA, Van Schie CH, Boulton AJM, Harkless LB Off-loading the diabetic foot wound: a randomized clinical trial [published correction appears in Diabetes Care. 2001;24:1509]. Diabetes Care. 2001;24:1019-1022.
13. Lipsky BA, Berendt AR Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev. 2000; 16(suppl 1):S42-S46.
14. Veves A., Falanga V., Armstrong DG, Sabolinski ML Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers. Diabetes Care. 2001; 24: 290-295.
15. Sams HH, Chen J., Kin LE Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatol Surg. 2002; 28: 698-703.
16. Brem H., Balledux J., Bloom T., Kerstein MD, Hollier L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg. 2000; 135: 627-634.
17. Espensen EH, Nicon BP, Lavery LA, Armstrong DG Use of subatmospheric (VAC) therapy to improve bioengineered tissue grafting in diabetic foot wounds. J Am Podiatr Med Assoc. 2002; 92: 395-397.
18. Edmonds M. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009;(8)1: 11-18.